Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103753 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL99299 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL201654 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL6358710 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL101263 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL102070 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL100742 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL26486 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL21880040 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL21880038 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 558 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476997-B | Liquid-crystalline medium | 默克专利股份有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-109790467-B | Liquid-crystalline medium | 默克专利股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| US-11168257-B2 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2021-11-09 | — | — | US | claimed |
| US-10982150-B2 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2021-04-20 | — | — | US | claimed |
| EP-3487955-B1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-05-20 | — | — | EP | claimed |
| CN-105992787-B | Organic semiconductor material | 东洋纺株式会社 | 2020-03-03 | — | — | CN | claimed |
| EP-3475389-B1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | claimed |
| US-20190241811-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-08-08 | — | — | US | claimed |
| WO-2019110355-A1 | BRANCHED ADIPIC ACID BASED ESTERS AS NOVEL BASE STOCKS AND LUBRICANTS | BASF SE (DE) | 2019-06-13 | — | — | WO | claimed |
| EP-3487955-A1 | LIQUID CRYSTALLINE MEDIUM | Merck Patent GmbH (DE) | 2019-05-29 | — | — | EP | claimed |
| WO-2018001919-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-01-04 | — | — | WO | claimed |
| CN-107384227-A | A kind of optic-solidified adhesive | 成都纳硕科技有限公司 | 2017-11-24 | — | — | CN | claimed |
| CN-107384226-A | A kind of environmentally friendly optic-solidified adhesive | 成都纳硕科技有限公司 | 2017-11-24 | — | — | CN | claimed |
| CN-104662018-B | Substituted Heterobicyclic compounds, composition and its medical applications | 阿迪维纳斯治疗有限公司 | 2017-10-24 | — | — | CN | claimed |
| CN-105518053-B | aliphatic polycarbonate compositions and methods | 诺沃梅尔公司 | 2017-07-21 | — | — | CN | claimed |
| EP-2086974-B1 | DIIMIDE-BASED SEMICONDUCTOR MATERIALS AND METHODS OF PREPARING AND USING THE SAME | POLYERA CORP (US) | 2013-07-24 | — | — | EP | claimed |
| CN-101951921-A | Be used for the treatment of cachectic ways and means | BIONERIS AB | 2011-01-19 | — | — | CN | claimed |
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | claimed |
| EP-2187892-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | Bioneris AB (SE) | 2010-05-26 | — | — | EP | claimed |
| WO-2009038533-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | BIONERIS AB (SE) | 2009-03-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | PYGM, GYS1, CPT1B | TSHR 1261/4885THRB 370/4885LMNA 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.